| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566246 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US8329198 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US8535695 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US9265812 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(5 years from now) | |
| US10695397 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11052126 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US10238709 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11510963 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11338011 | CHIESI | Method of treating diseases |
Feb, 2036
(11 years from now) | |
| US11141457 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(16 years from now) | |
Mycapssa is owned by Chiesi.
Mycapssa contains Octreotide Acetate.
Mycapssa has a total of 10 drug patents out of which 0 drug patents have expired.
Mycapssa was authorised for market use on 26 June, 2020.
Mycapssa is available in capsule, delayed release;oral dosage forms.
Mycapssa can be used as use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel, use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
The generics of Mycapssa are possible to be released after 28 December, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 26, 2023 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
MYCAPSSA family patents
